—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Illumina Inc (ILMN) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ILMN, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index HALO Growth 100 — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

HALO Growth 100 · as of 2026-10-06

DayWeekMonth3 months
ILMN−6.9%+0.6%+25.4%+45.6%
Longevity & Healthspan−1.9%−3.5%−4.0%—
HALO Growth 100+0.5%+0.7%−4.9%—

Against the index: 0.1 pts behind on the week, 30.3 pts ahead on the month; against its Longevity & Healthspan sleeve 29.4 pts ahead on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Mentioned on Closelooknet 1 piece · newest: Morning 10, “Markets — Nasdaq +1.5% before the open even as TLT breaks 78; Tokyo +3.3% on Micron's record quarter” (2026-10-01)

Mentioned on Closelooknet

Where ILMN appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.56 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How ILMN has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.56 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Illumina Inc moved 0.56% on average · correlation 0.11 · higher than 58% of US names
  • Beta, last 3 months 0.17 less rate-sensitive lately than over the year
  • On the 10 worst bond days +0.55% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +7.25% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against HALO Growth 100 · Longevity & Healthspan · 8 names with week and year-to-date

Peer group

HALO Growth 100 · Longevity & Healthspan

GLP-1 leaders, gene-editing platforms, diagnostics-at-scale, biopharma compounders. Demographics writes the demand curve.

Compared against ILMN on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Illumina Inc

ILMN in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Illumina builds the sequencing and array instruments, and the reagents and flow cells that run through them, used to read DNA and RNA. It sells whole-genome, exome and targeted sequencing kits and services to research centres, hospitals, government labs and biotech and diagnostics companies, mostly through direct sales and distributors. It also runs partnerships on oncology sequencing and on the data pipelines that turn raw reads into usable results. Illumina is based in San Diego.
Where it sits in the stack
Illumina carries no seat in Rubin, our AI build-out index; it sits in the HALO Growth 100, our growth index outside the megacaps, in the Longevity & Healthspan sleeve. That sleeve groups diagnostics-at-scale and gene-editing platforms whose demand follows demographics, and Illumina supplies the sequencing hardware those platforms are built on.
Who it is priced against
The diary's peer group for this sleeve pairs GLP-1 leaders and gene-editing platforms with diagnostics-at-scale names and biopharma compounders, including Eli Lilly, Regeneron, Vertex, Novo Nordisk, Amgen and Natera; the market also names Thermo Fisher Scientific as a direct competitor in sequencing.
Why Closelooknet tracks it
Illumina holds a seat in the HALO Growth 100 and carries a Closelooknet score, with momentum reading strongest and valuation weakest across the score's modules; the diary has not yet quoted it in an edition.
What the diary watches
Whether momentum keeps running ahead of valuation, or whether the gap narrows as analyst targets and the score's modules move against each other.

Illumina Inc (ILMN) trades on US exchanges. Constituent of HALO Growth 100.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 4 analyst actions on the wire · latest: price target by Guggenheim, 2026-10-01

The Street on this name

Analyst actions and the latest print for ILMN from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Guggenheim — target 305 from 226 Target raised to $305 from $226 (+12.6% to spot) 2026-10-01
  • Price target Leerink — target 300 from 220 Target raised to $300 from $220 (+9.6% to spot) 2026-09-29
  • Price target Piper Sandler — target 305 from 225 Target raised to $305 from $225 (+13% to spot) 2026-09-28

4 actions on the analyst wire since 2026-08-13: 4 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months · last 3.00 USD on 2024-06-25

Dividends and capital return

What ILMN pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months No cash distribution in the last twelve months earlier distributions show in the price series, see the years below
  • Last distribution 3.00 USD per share as the price series records it, within days of the ex-date 2024-06-25
  • By calendar year 2024: 3.00 USD (partial) first distribution recorded in the three-year window: 2024-06-25

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Illumina Inc (ILMN)?

Illumina Inc trades as ILMN on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is ILMN in a Closelooknet index?

Yes — Illumina Inc is a constituent of HALO Growth 100, as of 2026-10-07.

Where does ILMN trade against its moving averages?

Up 7.6% at the close: Above both trend lines; one of the day's strongest moves. As of 2026-10-05 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is ILMN doing against its Closelooknet index?

Over the past month Illumina Inc is +25.4% against −4.9% for the HALO Growth 100 — 30.3 points ahead of its index, as of 2026-10-06. Its Longevity & Healthspan sleeve is −4.0% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does Illumina Inc compare with its peers?

Against its peer group (HALO Growth 100 · Longevity & Healthspan), Illumina Inc (ILMN) sits 0.9% below its 52-week high, 33.0% above its 50-day average; Eli Lilly and Company (LLY) is 11.6% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Amgen Inc (AMGN) is 9.9% below. Put any of them next to ILMN in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Illumina Inc trade when bond yields rise?

Over the past year Illumina Inc had a beta of 0.56 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 58% of US names. On the 10 sessions in which long bonds fell most it moved +0.55% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about Illumina Inc?

Illumina Inc appears in 1 Closelooknet piece, most recently Morning 10: Markets — Nasdaq +1.5% before the open even as TLT breaks 78; Tokyo +3.3% on Micron's record quarter (2026-10-01). What Closelooknet said most recently: Rebalance done — Atlassian, Lenovo and Illumina give back weight as four indices reset to an equal share (Morning 10, 2026-10-01). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does Illumina Inc do?

Illumina builds the sequencing and array instruments, and the reagents and flow cells that run through them, used to read DNA and RNA. It sells whole-genome, exome and targeted sequencing kits and services to research centres, hospitals, government labs and biotech and diagnostics companies, mostly through direct sales and distributors. It also runs partnerships on oncology sequencing and on the data pipelines that turn raw reads into usable results. The diary's peer group for this sleeve pairs GLP-1 leaders and gene-editing platforms with diagnostics-at-scale names and biopharma compounders, including Eli Lilly, Regeneron, Vertex, Novo Nordisk, Amgen and Natera; the market also names Thermo Fisher Scientific as a direct competitor in sequencing.

Where does Illumina Inc sit in the AI build-out?

Illumina carries no seat in Rubin, our AI build-out index; it sits in the HALO Growth 100, our growth index outside the megacaps, in the Longevity & Healthspan sleeve. That sleeve groups diagnostics-at-scale and gene-editing platforms whose demand follows demographics, and Illumina supplies the sequencing hardware those platforms are built on. Illumina holds a seat in the HALO Growth 100 and carries a Closelooknet score, with momentum reading strongest and valuation weakest across the score's modules; the diary has not yet quoted it in an edition.

Does Illumina Inc pay a dividend?

No cash distribution shows in Illumina Inc’s price series over the last twelve months. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Illumina Inc recently?

The most recent analyst action on Illumina Inc on the Closelooknet wire is a price target by Guggenheim on 2026-10-01 (target 305 from 226). 4 actions on the analyst wire since 2026-08-13: 4 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for ILMN, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

same Closelooknet index seat first, then Diagnostics & Research. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.